Answers are grounded in this paper and cite their sources.
Encephalocraniocutaneous lipomatosis (ECCL;[MIM:613001]) is a rare sporadic RASopathy due to one of two mutually exclusive fibroblast growth factor receptor 1 (FGFR1) mutations p.N546K or p.K656E. These activating hotspot mutations are identified in affected tissues, but not in the peripheral blood of ECCL patients, and are likely the result of post-zygotic constitutional mosaicism promoting locally constitutive activation of the RAS-MAPK pathway [ 1 ]. The same FGFR1 mutations occur in subgroups of sporadic low-grade gliomas (LGG) [ 7 , 10 , 12 ] indicating probable intersection between ECCL and tumorigenesis, possibility further substantiated by reports of brain tumors in nine ECCL cases with wide-ranging histopathological subtypes [ 1 , 2 , 3 , 5 , 6 , 8 , 9 , 13 ].
No takes yet. Share an insight, caveat, or question.
Valera et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: